TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor, the company’s founders told MIT News. The device grew out of a 2017 MIT class project and uses vibration intended to affect movement signals; the source reports that 78% of patients in one trial reported benefits after 90 days of home use.
The U.S. Food and Drug Administration cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor, according to MIT News, which reported the clearance in February 2026. The device began as a 2017 MIT engineering-class project and delivers vibration intended to reduce tremors; its clearance marks a move from student prototype to a treatment available for adults with the condition.
The prototype was developed by students in MIT’s 2.009 Product Engineering Processes class. During a 2017 presentation at Kresge Auditorium, a man identified by MIT News as Michael, who had Parkinson’s disease, wore the wristband and attempted to draw a spiral, a task commonly used to assess tremor. The report says his drawing became more controlled after he switched on the device. That demonstration prompted requests from audience members who wanted the device for relatives, though the class team had only one prototype.
Encora was formed as a company in 2020. Its founders continued development through multiple hardware iterations and clinical testing, according to the MIT report. In one trial, 78 percent of patients reported benefits after 90 days of using the device at home. The report does not give the trial’s sample size or further details about how “benefits” were measured, so that figure should not be read as a measure of proven efficacy for every user.
Encora’s three founders still with the company are Daniel Carballo, Allison Davanzo and Kyle Pina, all members of the 2017 class team. The project first aimed to help people with Parkinson’s disease, but the company later focused on essential tremor. Carballo told MIT News that the team’s early clinical work and research led it to see essential tremor as a larger unmet need.
A Class Prototype Reaches Patients
The clearance gives adults with essential tremor another device-based option, rather than limiting the technology to a classroom demonstration or research prototype. Essential tremor causes shaking, often in the hands, and can interfere with everyday tasks. MIT News describes the initial demonstration as a response to the practical effects tremors had on Michael’s work and daily life.
The development also shows how much work separates an engineering concept from a medical product. The team spent years refining hardware and conducting clinical trials before the reported FDA clearance. That timeline matters to patients and caregivers: the dramatic 2017 stage demonstration was an individual experience, not by itself evidence of broad effectiveness. The reported trial result offers a separate data point, but the available source does not provide enough detail to judge the strength or limits of the evidence.
For people considering the device, the clearance is a regulatory milestone, not a guarantee that it will work for every person or replace other care. The report says it is intended to help adults with essential tremor; it does not establish that the device is cleared for Parkinson’s-related tremors.
Products Worth Considering
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Oura Ring 4 Smart Ring – Silver – Size 8
Philips Sonicare DiamondClean 9500 Smart Electric Toothbrush with 2 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
From MIT Course to Company
The project began with a brainstorming exercise in MIT’s product engineering course. Carballo suggested using mechanical vibration to influence the body’s movement-control system. The class team selected the idea despite his own doubts about whether it could be built within a semester. A rough prototype—described by Carballo as a foam-core box with a Raspberry Pi and wires—was ready shortly before the class’s final presentation.
After the public demonstration, some team members pursued support from MIT’s entrepreneurial programs, including MIT Sandbox, MIT FUSE and the MIT Venture Mentoring Service. The project became Encora Therapeutics in 2020. The team’s initial focus was Parkinson’s disease and it conducted a 2022 clinical trial with 20 Parkinson’s patients in collaboration with Mass General Brigham, according to MIT News. The company later shifted its focus to essential tremor, which Carballo said had seen less innovation than Parkinson’s disease.
The device uses mechanical vibration delivered at the wrist. Carballo described the idea as sending signals through the sensory system that may affect the brain’s movement-control feedback loops. The MIT report presents this as the team’s rationale; it does not offer a detailed account of the device’s mechanism or clinical evidence beyond the patient-reported result.
““It’s been a long and difficult — very difficult — journey, but also very rewarding, especially when we get feedback from patients.””
— Daniel Carballo, Encora Therapeutics co-founder and vice president of strategy, as quoted by MIT News
Evidence and Use Limits
The MIT report does not identify the device’s commercial name, provide the date of the FDA decision beyond saying it occurred in February, or include the FDA’s clearance documentation. It also does not specify the device’s exact regulatory pathway, detailed instructions for use, price, availability, or whether insurance covers it.
The reported 78 percent patient-benefit figure lacks key details in the source, including the number of participants, the trial design, the definition of benefit and whether results were compared with a control group. It is also unclear how long any reported effects lasted beyond the 90-day home-use period. The stage demonstration involved one person with Parkinson’s, while the clearance reported here applies to adults with essential tremor; the source does not say the device is cleared for Parkinson’s-related tremors.
Availability and Further Evidence
The next practical questions concern when and where adults with essential tremor can obtain the device, what it will cost and how clinicians should advise patients about its use. The MIT News report does not provide those details or set out a timeline for broader access. Patients should seek product and care guidance from a qualified health professional rather than treating one person’s experience or the reported trial result as a prediction of their own outcome.
Further information from Encora or the FDA could clarify the clearance’s scope, the evidence reviewed and the device’s labeling. More complete trial data would also help patients and clinicians assess how many people may benefit, what outcomes were measured and whether effects persist with continued use.
Key Questions
What did the FDA clear?
The FDA cleared Encora Therapeutics’ wrist-worn vibration device to help adults with essential tremor, according to MIT News. The report does not give the product’s commercial name or detailed labeling.
Does the clearance cover Parkinson’s tremors?
The reported clearance is for adults with essential tremor. Although the original class project was inspired by Parkinson’s tremors and a man with Parkinson’s demonstrated the prototype, the source does not say the device is cleared for Parkinson’s-related tremors.
What evidence does the report describe?
MIT News reports that 78 percent of patients said they benefited after 90 days of home use in one trial. The article does not supply the trial size, comparison group or definition of benefit, limiting what can be concluded from the figure alone.
When will patients be able to get the device?
The source does not state when the device will be available, its price or whether insurance will cover it. Those details remain unreported.
Source: hn
